Neoadjuvant therapy with conservative surgery for jaw tumor
Part of Cancer clinical trials.
This trial tests if taking targeted drugs before surgery can reduce the amount of jawbone that needs to be removed, compared to going straight to surgery. It is for people with a specific type of jaw tumor that has a BRAF V600E mutation.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 12 years old.
- You have a type of jaw tumor called ameloblastoma that has a specific genetic change (BRAF V600E mutation).
- Your doctor recommends removing part of your jawbone or upper jaw with surgery.
- You are healthy enough for daily activities (ECOG score 0 or 1).
- You are willing to take targeted pills (dabrafenib and trametinib) before surgery.
- You have not had treatment with similar targeted drugs before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether taking two targeted drugs (dabrafenib and trametinib) before surgery can shrink a specific type of jaw tumor called ameloblastoma. The tumor must have a certain genetic change (BRAF V600E mutation) and require a large jaw surgery. The goal is to see if the drugs make surgery less extensive or more successful.
This trial tests a computer method to plan safe removal of a non-cancerous jaw tumor called ameloblastoma. It may help surgeons see the exact area to remove to reduce the chance of the tumor coming back.
This trial tests whether giving a targeted therapy pill (which attacks cancer cells with a BRAF mutation) before and after surgery can help treat anaplastic thyroid cancer that hasn't spread to other organs. It's for people whose cancer has a specific gene change (BRAF V600E or V600K) and who are healthy enough for surgery.
This trial tests a targeted treatment given before and after surgery for people with a specific type of early-stage lung cancer that has a BRAF V600 or MET exon 14 mutation. The goal is to see if the treatment helps shrink the tumor before surgery and prevent it from coming back afterward.
This study tests a combination of an immunotherapy drug (Benmelstobart), a targeted therapy (Anlotinib), and standard chemotherapy given before surgery for advanced oral cancer. The goal is to see if this approach can shrink the tumor and improve outcomes.
This Phase 2 trial tests a targeted treatment for adults with papillary craniopharyngioma that has a specific BRAF change (V600E). It may help shrink or control the tumor, especially when surgery is not expected to remove it safely.
Hear when a new Ameloblastoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.